SCHEMBL2795058

SCHEMBL2795058

O=C(Nc1ccc(Oc2ccnc3[nH]ncc23)cc1)Nc1cc(CCF)cc(C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 12/20 0.60
BRAF P15056 8/20 0.54
KDR P35968 6/20 0.54
MAPK14 Q16539 2/20 0.54
TNNI3K Q59H18 2/20 0.54
RAF1 P04049 1/20 0.46
PDGFRB P09619 1/20 0.46
KIT P10721 1/20 0.46
PDGFRA P16234 1/20 0.46
FGFR2 P21802 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2795404 0.95 FLT3 (0.58) FLT3BRAFKDRMAPK14TNNI3K
SCHEMBL2795108 0.94 FLT3 (0.57) FLT3BRAFKDRMAPK14TNNI3K
SCHEMBL2793519 0.93 FLT3 (0.57) FLT3BRAFKDRMAPK14TNNI3K
SCHEMBL2795274 0.89 FLT3 (0.56) FLT3BRAFKDRMAPK14TNNI3K
SCHEMBL2795051 0.89 FLT3 (0.59) FLT3BRAFKDRMAPK14TNNI3K
SCHEMBL2793680 0.87 BRAF (0.71) BRAFKDRMAPK14TNNI3K
SCHEMBL2795128 0.83 FLT3 (0.55) FLT3BRAFKDRMAPK14TNNI3K
SCHEMBL2795400 0.82 BRAF (0.69) BRAFKDRMAPK14TNNI3K
SCHEMBL2794342 0.81 BRAF (0.68) BRAFKDRMAPK14TNNI3K
SCHEMBL2791845 0.80 FLT3 (0.53) FLT3BRAFKDRMAPK14TNNI3K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1921078-B1 MULTIKINASE INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2013-01-09 EP claimed
US-8299252-B2 Pyrazolopyridine and pyrrolopyridine multikinase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-30 US claimed
US-20100168430-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-01 US claimed
EP-1921078-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-14 EP claimed
EP-1921078-B1 MULTIKINASE INHIBITOR CHUGAI PHARMACEUTICAL CO LTD (JP) 2013-01-09 EP disclosed
US-8299252-B2 Pyrazolopyridine and pyrrolopyridine multikinase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-30 US disclosed
US-8299252-B2 Pyrazolopyridine and pyrrolopyridine multikinase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-30 US disclosed
US-8299252-B2 Pyrazolopyridine and pyrrolopyridine multikinase inhibitors CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-30 US disclosed
US-20100168430-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-01 US disclosed
US-20100168430-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-01 US disclosed
US-20100168430-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-01 US disclosed
EP-1921078-A1 MULTIKINASE INHIBITOR CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168430-A1 MULTIKINASE INHIBITOR REN, RAF1, CHUK FLT3 217/4885BRAF 84/4885KDR 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.